

Genetic Testing for PTEN Hamartoma Tumor Syndrome

Last Review Date: December 10, 2021

Number: MG.MM.LA.37C6

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

PTEN hamartoma tumor syndrome (PHTS) is an autosomal group of disease conditions caused by a mutation of the PTEN gene on chromosome 10q23 and includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS) and Adult Lhermitte-Duclos disease (ALDD). CS is the only PHTS associated with a documented predisposition to cancer, however other PHTS may have cancer risks comparable to CS. The primary clinical manifestation of PHTS is a benign hamartomatous tumor.

Related Medical Guideline

[Genetic Counseling and Testing](#)

Guideline

PTEN gene testing is considered medically necessary when **any** of the following criteria are met:

1. 1st or 2nd degree relative has known PTEN mutation
2. Member has personal history of:
 - a. Adult Lhermitte-Duclos disease (ALDD)
 - b. Bannayan Riley-Ruvalcaba syndrome (BRRS)
 - c. Autism spectrum disorder and macrocephaly
 - d. Proteus Syndrome (hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi and hyperostoses)
3. Member meets any of the following criteria for Cowden/PHTS syndrome:
 - a. At least 2 biopsy proven trichilemmomas
 - b. Macrocephaly plus ≥ 1 of the other [major criteria](#)
 - c. ≥ 3 [major](#) criteria without macrocephaly
 - d. 2 [major](#) and ≥ 2 of the [minor](#) criteria
 - e. 1 [major](#) and ≥ 3 [minor](#) criteria
 - f. ≥ 4 [minor](#) criteria

4. Member has a family history of both of the following:
 - a. At-risk relative with a clinical diagnosis of CS/PHTS or BRRS and no previous genetic testing
 - b. At-risk relative has 1 [major](#) criteria or 2 [minor](#) criteria

Major and Minor Criteria for PTEN Genetic Testing

Major	Minor
Breast cancer	Autism spectrum disorder (without macrocephaly)
Follicular thyroid cancer	Mental retardation (IQ < 75)
Endometrial cancer	Papillary thyroid cancer (papillary or follicular)
Multiple GI hamartomas or ganglioneuromas	Thyroid structural lesions (e.g., adenoma, nodule(s), goiter)
Macrocephaly (≥ 97th percentile; 58 cm in adult women, 60 cm in adult men)	Colon cancer
Mucocutaneous lesions	Renal cell carcinoma
One biopsy-proven trichilemmoma	Single gastrointestinal hamartoma or ganglioneuroma
Multiple palmoplantar keratoses	Esophageal glycogenic acanthoses (≥ 3)
Multiple or extensive oral mucosal papillomatosis	Lipomas
Multiple cutaneous facial papules (often verrucous)	Testicular lipomatosis
Macular pigmentation of glans penis	Vascular anomalies (including multiple intracranial developmental venous anomalies)
≥ 3 mucocutaneous neuromas	

Limitations/Exclusions

PTEN gene testing is considered experimental and investigational for all other conditions that do not meet the above criteria

Applicable Procedure Codes

81321	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
81322	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
81323	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant

References

1. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol.* 2009;27(35):5924-5930.
2. Marsh DJ, Coulon V, Lunetta KL et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet.* 1998; 7(3):507-515.
3. National Comprehensive Cancer Network (NCCN). NCCN guidelines Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic. V1.2022. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed December 16, 2021.
4. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *J Natl Cancer Inst.* 2013; 105(21):1607-1616.

Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. *J Med Genet.* Aug 2011;48(8):505-512. PMID 21659347